HCPCS Level II code J2506 denotes a 0.5 mg unit of pegfilgrastim (excludes biosimilar), a long-acting granulocyte colony-stimulating factor used to prevent chemotherapy-induced neutropenia. This code is nationally significant because pegfilgrastim is commonly used in oncology care to reduce febrile neutropenia, shorten hospital stays, and support continuation of planned chemotherapy dosing. Accurate coding for biologic injectables affects claims processing, medical necessity review, and drug utilization monitoring across payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for pegfilgrastim, typical sites of service for administration, and the implications of using a non-biosimilar product distinct from biosimilars. The publication summarizes reimbursement and billing benchmarks, common payer policies and coverage considerations, and relevant coding nuances for dose-based HCPCS drug units. Where input data is not provided, the report notes that specific fields are not available.

This summary provides clinicians, billing professionals, and policy analysts with concise reference information to support correct use of HCPCS Level II code J2506 in outpatient oncology and infusion settings.